Affirmed Therapeutics BV (NASDAQ:AFMD) fell 6% on Tuesday . The stock traded as low as $2.68 and last traded at $2.68, with a volume of 52,012 shares traded. The stock had previously closed at $2.85.

Several research firms have weighed in on AFMD. Leerink Swann began coverage on Affirmed Therapeutics BV in a report on Saturday, April 2nd. They issued a “buy” rating for the company. BMO Capital Markets began coverage on Affirmed Therapeutics BV in a report on Monday, April 11th. They issued an “outperform” rating and a $7.00 price objective for the company. Wells Fargo & Co. reiterated a “buy” rating on shares of Affirmed Therapeutics BV in a report on Wednesday, May 18th. Finally, Jefferies Group dropped their price objective on Affirmed Therapeutics BV from $5.00 to $4.00 and set a “hold” rating for the company in a report on Thursday, May 19th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $9.46.

The company’s 50-day moving average price is $3.05 and its 200-day moving average price is $3.64. The stock’s market capitalization is $87.33 million.

Affirmed Therapeutics BV (NASDAQ:AFMD) last issued its quarterly earnings data on Wednesday, May 18th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by $0.08. The business earned $1.90 million during the quarter, compared to the consensus estimate of $1.88 million. The company’s revenue was down 24.0% compared to the same quarter last year. On average, equities analysts expect that Affirmed Therapeutics BV will post ($0.95) earnings per share for the current year.

An institutional investor recently raised its position in Affirmed Therapeutics BV stock. Tekla Capital Management LLC increased its stake in Affirmed Therapeutics BV (NASDAQ:AFMD) by 29.0% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 294,213 shares of the biopharmaceutical company’s stock after buying an additional 66,130 shares during the period. Tekla Capital Management LLC owned about 0.97% of Affirmed Therapeutics BV worth $2,095,000 as of its most recent SEC filing.

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.